Aion Labs
ProPhet's aim is to bring down the time and cost of finding molecules for new drug targets.
The Israel-based company is the result of AION Labs' fifth startup challenge.
TenAces will develop an AI platform to help identify protein interactions that naturally occur in the body to assist with targeted protein degradation.
DenovAI will create an AI-powered platform to discover potential antibodies from scratch, then suggest which ones can be used as effective drugs.
Mati Gil, CEO of AION Labs, describes how its new startup OMEC.AI came to fruition and what it aims to accomplish for drug discovery and development.
The lab, which works with AstraZeneca, Merck, Pfizer, Israel Biotech Fund, Teva Pharmaceuticals, and Amazon Web Services, is currently accepting applicants for its new challenge.